Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Cash and Short Term Investments

Last Annual Value

235.70M

3-Year CAGR

23%

5-Year CAGR

23%

10-Year CAGR

19%

Savara Inc.

Savara Inc. Competitors Analysis of Cash and Short Term Investments

SVRA · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
235.70M
13.2%7.9%33.2% 
667.24M
16.3%5.2%25.7%
359.80M
2.5%14.4%12.1%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
167.86M
18.1%32.5%45.1%
414.80M
21.6%N/AN/A
343.14M
0.6%-6.7%N/A
256.00M
8.0%-3.3%N/A
306.09M
-2.6%7.7%26.6%
PROK logo
ProKidney Corp.
NASDAQ:PROK
270.02M
-9.4%67.4%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25